Efficient Premarket Applications Three FDA Submission Paths That Require Less Time,
Money and Effort
What is your premarket application strategy?
Devicemakers can pass over the most common pathways in favor of three lesser-used programs that require less time, money and effort:
The De Novo program
Early Feasibility/First-in-Human Studies
The Expedited Access Pathway
All three of these options bypass the lengthy clinical trial and literature search processes and offer opportunities for rapid FDA feedback that can strengthen your application’s chance of success.
This report explains the criteria for each pathway, how to determine which one is right for your device and strategies for success. Fictional cases illustrate how the different pathways can be used. You will learn:
The benefits and requirements of the de novo, early feasibility/first-in-human and expedited access pathways
How to determine which pathway is the most efficient for you
How the passage of the 21st Century Cures Act and the impending MDUFA goals are potential game-changers in pathway determination
How to optimize effective communications with the FDA, depending on which pathway is best suited for your product
Order your copy of Efficient Premarket Applications and save time and money in the submission process.
Order Your Copy Today
PDF Edition — $397
Who Will Benefit
Clinical and Medical Affairs
Save money with a license agreement allowing significant numbers of users access to an electronic version of this book. For multi-user access to multiple titles, FDAnews offers the FDAnews Online Library — a personalized collection of FDAnews publications that is fully searchable. Contact Customer Service for a quote or more information.
Not satisfied with your publication? For the PDF version, you must notify FDAnews within 24 hours of receipt of purchase and we will refund 100 percent of your purchase price.